Qualampur: A center for regenerative medicine Stemcell SDN BHD has allocated RM20 million to increase infrastructure and improve access to its services in Malaysia and the entire region.
This investment will support the expansion efforts of Stemsel First, including establishing clinics, establishing cooperation with local partners, and facilities for state -of -the -art technology transfer.
“We are actively expanding in Indonesia and Thailand. Our clinic in Thailand is already on, while in Indonesia, we are demanding strategic partnership with local laboratories. Although we do not currently plan to install a clinic in Indonesia, we are searching for cooperation with hospitals in the region.
“This expansion aligns with our commitment to healthcare access and innovation, ensuring that more people benefit from our groundbreaking medical solutions,” stated Alan Law, Chief Operating Officer of Stemsel First Group. Sunbiz,
Stemcell was included the first three years ago, focusing on advanced genes and cell therapy. The company provides advanced treatment for chronic conditions such as Parkinson’s, diabetes and cancer.
The law stated that one of the latest offerings of Stemsel First is a multiple cancer early detection (MCED) test, which allows individuals to assess the possibility of cancer development in the coming years through a simple 10ml blood test.
He said that the company’s mced test is different from the traditional cancer screening available in hospitals.
While standard blood tests are widely known, MCED is still relatively new in Malaysia and is not yet familiar with the general public.
The law reported that, unlike regular blood tests, MCED requires a special process. The collected blood samples are sent to a foreign laboratory for advanced analysis, which takes about a month to produce the result.
“The process involves complex scientific analysis, which allows us to screen for nine types of cancer in an early stage – even before the symptoms appear. Traditional blood tests cannot provide this level prediction insight.
“In terms of cost, msed is more expensive due to its advanced technology and logical needs. While standard blood tests ranging from RM80 to RM1,000 to premium screening, MCED currently costs between RM3,000 and RM4,000 costs. This price reflects cutting analysis and comprehensive identification capabilities,” the law said.
He said that the customer base of Stemsel First could be classified into two main groups.
The first group consists of high -risk individuals of cancer, especially with family history of the disease. If a person’s parents or close relatives have been diagnosed with specific types of cancer, they want to undergo a test to assess whether they have inherited any genetic risk factor.
The second group consists of individuals with moderate to high net worth prioritizing their long -term health. They choose the option of mced as an active remedy to ensure that to stay healthy in the coming years.
“Currently, Malaysia is our primary market, as MCED was launched less than six months ago. At this stage, we are specially offering service in Malaysia, while working to resolve logical challenges before expanding in Thailand and Indonesia,” Law said.
Stemcell is first taking a structured approach to get cooperation in Thailand and Indonesia.
The law said that the first step is working properly on the potential laboratory partners to ensure that they meet the company’s stringent medical standards.
“We need to clinically certified the laboratories and be an officer of CGMP certification, ensuring that they can perform essential procedures such as centrifugation and DNA extraction. Once we identify appropriate partners, we will move forward with dialogue, such as pricing, turning time and workforce capacity.
“For the timeline, we are convinced in acquiring a partnership this year. However, our immediate attention is on Thailand, as we are allocating resources strategically to ensure a smooth expansion,”
The law also said that one of the major challenges has always been bridging the difference between basic research and market implementation. “However, opportunities are expanding, especially with the increasing prominence of Asia.”
Globally, the level of education is increasing, and the more skilled talent is entering the industry, which has a rapid competitive and dynamic market, he said.
The law said, “Malaysia, Indonesia and Thailand are progressing at this place, each developing their strategy and solutions. Singapore has also established an attendance in the region, contributing to the overall progress of the region,” the law said.
When asked about collaborating with insurance companies, the law said that such partnership would be an ideal landscape for the first stemcell, as pricing is one of the biggest challenges in medical remedies.
“High treatment costs can prevent patients from reaching life-saving care. Insurance coverage will not only make our services more accessible, but will also significantly increase our long-term revenue.
“Our goal has always been to work with the insurers, but will have to undergo a rigorous assessment process. Insurance companies work on the basis of risk calculation, determining what they can cover and how premium structures are.
“To get their support, we must provide comprehensive data for evaluation. Only after this fully evaluated they can take an informed decision to offer coverage for our services,” the law said.
